Aryeh Sand

Partner

EMAIL

aryeh.sand@solomonpartners.com

PHONE

(212) 508-1624

Aryeh Sand is a Partner in the Healthcare group focused on nuclear medicine, radiopharmaceutical, contrast media and diagnostic imaging, and specialty and generic pharmaceuticals. He joined the firm in 2022 as Managing Director.

Aryeh has 15+ years of healthcare investment banking experience and specializes in advising clients in the nuclear medicine, radiopharmaceutical, contrast media and diagnostic imaging, and specialty and generic pharmaceuticals industries. He has advised boards of directors and special committees as well as companies on a broad range of transactions, including mergers, acquisitions, divestitures, leveraged buyouts, restructurings and capital raising solutions.

Prior to joining Solomon Partners, Aryeh was a Managing Director and Head of Healthcare Investment Banking at TAP Advisors where he spent six years building the firm’s healthcare effort. Prior to TAP, Aryeh was a founding member and senior banker in Mizuho’s Healthcare Investment Banking group. Over the past decade, Aryeh has advised or has served as a lead financing banker on numerous key healthcare transactions with a total transaction value of over $100 billion. Aryeh has worked with leading companies, including Lantheus, Curium (Mallinckrodt Nuclear Medicine), SOFIE, BWXT Medical, Allergan, Amgen, Gilead, Azurity Pharmaceuticals, Upsher-Smith, and Alora Pharmaceuticals.

Aryeh earned an Honours B.Comm degree from the University of Toronto.

Select Recent Transactions

Served as financial advisor to PharmaLogic, a portfolio company of Webster Equity Partners and MedEquity Capital, on its acquisition of Agilera Pharma AS
June 2025
Served as financial advisor to GE HealthCare on its acquisition of the remaining 50% stake in Nihon Medi-Physics
June 2025
Serving as financial advisor to Lantheus on the pending sale of its SPECT business to SHINE Technologies
May 2025
Served as financial advisor to Lantheus on its acquisition of Evergreen Theragnostics, with an upfront value of $275M and total value of up to $1B
April 2025
Served as financial advisor to SOFIE Biosciences on its growth investment from Trilantic North America
June 2024
Served as financial advisor to ARTMS Inc. on its sale
April 2024
Served as financial advisor to Lantheus on the sale of its Somerset facility to Perspective Therapeutics
March 2024

Latest Insights

Reflections On 2024 And Vision For The Future

2024 was a milestone year for Solomon Partners. Not only was it a record revenue year, we also meaningfully diversified…

Healthcare Technology & Tech-Enabled Services – 2022 Annual Review

Friends and Colleagues, With another year of M&A and financings in the books, we’re pleased to provide you with our…

Solomon Partners Expands Healthcare Team with Hiring of Aryeh Sand

Solomon Partners Expands Healthcare Team with Hiring of Aryeh Sand Veteran investment banker brings over 12 years of experience advising…